NCT05381038 is a Phase 1, PHASE2 clinical trial of QPOP in Solid Tumor, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT05381038?

NCT05381038 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT05381038?

Interventions in NCT05381038: QPOP, CURATE.AI, Azacitidine + docetaxel, Azacitidine + paclitaxel, Azacitidine + irinotecan.

What condition does NCT05381038 study?

NCT05381038 studies Solid Tumor, Gastrointestinal Cancer, Breast Cancer.

Is NCT05381038 still recruiting?

NCT05381038 is currently recruiting now. Last updated 23 September 2025.

Last reviewed 2025-09-23 · How we verify

NCT05381038

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

Recruiting now Phase 1, PHASE2 Last updated 23 September 2025

What this trial tests

Phase 1, PHASE2 trial testing QPOP in Solid Tumor in 10 participants. Currently enrolling.

Timeline

13 February 2023

Primary endpoint
4 October 2026

4 April 2027

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	13 February 2023
Primary completion	4 October 2026
Estimated completion	4 April 2027
Sites	1 location across Singapore

Drugs / interventions tested

QPOP
CURATE.AI
Azacitidine + docetaxel — full drug profile →
Azacitidine + paclitaxel — full drug profile →
Azacitidine + irinotecan — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →
Gastrointestinal Cancer — all drugs for Gastrointestinal Cancer →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 99, any sex, with Solid Tumor or Gastrointestinal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot feasibility study aims to set the foundation to investigate the applicability of QPOP drug selection followed by CURATE.AI-guided dose optimisation of the selected azacitidine combination therapy for solid tumours using CURATE.AI within the current clinical setting. QPOP will identify drug interactions towards optimal efficacy and cytotoxicity from the pre-specified drug pool based on ex vivo experimental data from the individual participant's tissue sample model. With these drug interactions, QPOP will identify the optimal drugs for the specific participant whose biopsy provided the cells for the ex vivo experimentation. Subsequently, CURATE.AI will be used to guide dosing for the selected combination therapy for that participant. Individualised CURATE.AI profiles will be generated based on each participant's response to a set of drug doses. Subsequently, the personalised CURATE.AI profile will be used to recommend the efficacy-driven dose. CURATE.AI will operate only within the safety range for each drug pre-specified for each participant. This pilot feasibility study will inform the investigators on the logistical and scientific feasibility of performing a large-scale randomised controlled trial (RCT) with the selected azacitidine combination therapy regimens and response markers. A secondary objective is to collect toxicity and efficacy data using established and exploratory response markers within and in-between cycles as exploratory outcomes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Human disease models in drug development.
Loewa A, Feng JJ, Hedtrich S. · · 2023 · cited 164× · PMID 37359774 · DOI 10.1038/s44222-023-00063-3
Tribulations and future opportunities for artificial intelligence in precision medicine.
Carini C, Seyhan AA. · · 2024 · cited 67× · PMID 38702711 · DOI 10.1186/s12967-024-05067-0
Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
Derouane F, van Marcke C, Berlière M, Gerday A, et al · · 2022 · cited 54× · PMID 36010869 · DOI 10.3390/cancers14163876
Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
Yin J, Gu T, Chaudhry N, Davidson NE, et al · · 2023 · cited 25× · PMID 38268926 · DOI 10.3389/fimmu.2023.1325615
N-of-1 medicine.
Wang P, Leong QY, Lau NY, Ng WY, et al · · 2024 · cited 5× · PMID 38527301 · DOI 10.4103/singaporemedj.smj-2023-243
Comparative epigenomics to clinical trials in human breast cancer and canine mammary tumor.
Jeong SJ, Lee KH, Cho JY. · · 2025 · cited 3× · PMID 40115961 · DOI 10.1080/19768354.2025.2477024
Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy.
de Nigris F, Meo C, Palinski W. · · 2023 · cited 3× · PMID 37681936 · DOI 10.3390/cells12172204
Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response.
Tsukamoto Y, Hirashita Y, Shibata T, Fumoto S, et al · · 2023 · cited 3× · PMID 37627132 · DOI 10.3390/cancers15164104

Verify or expand the search:

Other trials of QPOP

Trials testing the same drug.

NCT05177432 — Quadratic Phenotypic Optimisation Platform (QPOP) Utilisation to Enhance Selection of Patient Therapy Through Patient De · Phase 1 · unknown

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05381038 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 23 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05381038.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing